Therapeutics News and Research

RSS

Astrazeneca Licenses 3 X-Chem Drug Discovery Programs

...

24 Sep 2013

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.

23 Sep 2013

New regulatory mechanism could help develop novel therapies for cancer

Molecular microbiologists at the University of Southern California (USC) have uncovered intricate regulatory mechanisms within the cell that could lead to novel therapeutics for the treatment of cancer and other diseases.

23 Sep 2013

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with the National Cancer Institute (NCI), part of the NIH, and the Center for Advancing Innovation.

21 Sep 2013

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.

21 Sep 2013

Google Eyes Wider Healthcare Footprint With Tech-Focused Calico

...

19 Sep 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

CTI completes sale of 15,000 shares to Quogue Capital

Cell Therapeutics, Inc. today announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

19 Sep 2013

EpimiRNA Consortium concentrates on developing novel mRNA-based therapeutics to prevent epilepsy

Over 50 million people across the world suffer from epilepsy, making it the most common serious neurological disorder for which there is no cure. The causes for epilepsy are insufficiently understood with currently available treatments being sub-optimal and with a significant proportion of patients not responding

19 Sep 2013

UAB Comprehensive Cancer Center celebrates grand opening of Wallace Tumor Institute

On Friday, Aug. 23, the University of Alabama at Birmingham Comprehensive Cancer Center celebrated the public grand opening of the renovated Lurleen B. Wallace Tumor Institute (WTI).

18 Sep 2013

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.

18 Sep 2013

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

A preclinical study led by researchers at Children's National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy.

18 Sep 2013

Boston Scientific announces positive results from REPRISE II clinical trial of Lotus Valve System

Boston Scientific Corporation reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the Lotus™ Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement.

17 Sep 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Research finding offers new approach to treating melanoma

Scientists at Sanford-Burnham Medical Research Institute today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1, plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.

17 Sep 2013

Flecainide, encainide drugs increase risk of sudden cardiac death

Scientists have discovered that a drug which increases the risk of sudden cardiac death interacts with mistranslated protein-coding genes present in heart muscle.

17 Sep 2013

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Relmada Therapeutics collaborates with the Malvern Consulting Group

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has signed a collaboration agreement with the Malvern Consulting Group as clinical and regulatory advisor.

16 Sep 2013

Researchers report first experimental evidence that supports theory of buckyball

Researchers at the Virginia Tech Carilion Research Institute have reported the first experimental evidence that supports the theory that a soccer ball-shaped nanoparticle commonly called a buckyball is the result of a breakdown of larger structures rather than being built atom-by-atom from the ground up.

16 Sep 2013

MJFF Forms Research Tool Development Consortium For Parkinson's

...

13 Sep 2013

Therapeutics News and Research

Astrazeneca Licenses 3 X-Chem Drug Discovery Programs

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

New regulatory mechanism could help develop novel therapies for cancer

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

Google Eyes Wider Healthcare Footprint With Tech-Focused Calico

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

CTI completes sale of 15,000 shares to Quogue Capital

EpimiRNA Consortium concentrates on developing novel mRNA-based therapeutics to prevent epilepsy

UAB Comprehensive Cancer Center celebrates grand opening of Wallace Tumor Institute

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

Boston Scientific announces positive results from REPRISE II clinical trial of Lotus Valve System

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

Research finding offers new approach to treating melanoma

Flecainide, encainide drugs increase risk of sudden cardiac death

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Relmada Therapeutics collaborates with the Malvern Consulting Group

Researchers report first experimental evidence that supports theory of buckyball

MJFF Forms Research Tool Development Consortium For Parkinson's

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News